Wakefit vs. Corona Remedies: Which IPO Should You subscribe ?

Two major IPOs open on December 8th. One is a household consumer brand, the other a profitable pharma giant. We break down the financials, GMP, and valuations to tell you where to put your money.

The first week of December 2025 is bringing a massive clash to Dalal Street. Two very different companies—Wakefit Innovations (the D2C home solutions leader) and Corona Remedies (a high-growth pharmaceutical player)—are launching their IPOs on the same day: December 8, 2025.

For investors with limited capital, the big question is: Which one deserves your subscription?

Should you go for the brand you see on Instagram every day, or the quiet pharma performer making solid profits? Here is our deep-dive comparison.

1. The Head-to-Head Snapshot

Feature	Wakefit Innovations	Corona Remedies
Sector	Home & Sleep Solutions (D2C)	Pharmaceuticals
Price Band	₹185 – ₹195	₹1,008 – ₹1,062
Lot Size	76 Shares	14 Shares
Min Investment	₹14,820	₹14,868
Issue Size	₹1,288 Cr	₹655 Cr
Listing Gain (Est.)	~18% (Moderate)	~31-34% (Strong)
Our Verdict	High Risk / Long Term	Subscribe for Listing Gains

 

2. The Case for Corona Remedies (The "Safe" Bet)

Corona Remedies is an India-focused specialty pharma company known for its women's health and cardio-diabetic products.

• Financial Health: Unlike many modern IPOs, Corona is a cash-generating machine. They have reported consistent profit growth for the last three years.
  • Revenue (FY25): ₹1,202 Cr (Up 18%)
  • Net Profit (FY25): ₹149 Cr (Up 65%)
• Valuation: At a P/E ratio of roughly 43x, it is priced fairly compared to industry peers like Abbott India or JB Chemicals.
• Grey Market Premium (GMP): The market is buzzing. As of December 7, the GMP is hovering around ₹330-365, suggesting a strong listing gain of over 30%.

The Downside: The entire IPO is an Offer for Sale (OFS). This means the money you invest goes to existing shareholders (promoters & investors) to buy them out, not into the company for growth.

3. The Case for Wakefit Innovations (The "High-Growth" Bet)

Wakefit needs no introduction. They disrupted the mattress market and are now a full-fledged home solutions brand.

• Turnaround Story: Wakefit has been loss-making for years (FY23, FY24, FY25). However, in a major surprise, they turned profitable in the first half of this year (H1 FY26), posting a profit of ₹35.57 Cr.
• Brand Power: They are the market leader in the D2C sleep space with a massive omnichannel presence (125+ stores).
• Valuation Concerns: At the upper price band, the valuation looks steep. Some analysts peg the P/E at over 160x based on recent earnings, which is significantly more expensive than established players.
• Grey Market Premium (GMP): The excitement is moderate. The GMP is currently around ₹36, indicating a modest listing gain of roughly 18%.

4. Final Verdict: Which One to Pick?

If you can only pick one, the data points to Corona Remedies.

• Subscribe to Corona Remedies if: You want a safer bet with a higher probability of listing gains (30%+) and a company with a proven track record of profits. The strong anchor book interest (₹195 Cr raised from big names like SBI and ICICI Pru) confirms institutional confidence.
• Subscribe to Wakefit if: You are a high-risk investor who believes in the long-term consumption story of India. While the listing pop might be smaller, Wakefit could be a multi-bagger if they sustain their newfound profitability.

Recommendation: Corona Remedies is the winner for this week's allocation.

 

 

How To Apply for the IPO?

• Login or Open demat account with JM Financial Services / JM PRO app: Open the JM PRO app or JM Financial Services website and log in with your credentials. 
• Locate the IPO Section: Navigate to the 'IPO' section on the platform. 
• Select IPO: Find and select the IPO from the list of open IPOs. 
• Enter the Lot Size: Specify the number of lots you want to bid for. 
• Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application. 
• Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN. 

How To Check the Allotment Status of IPO?

Steps to check IPO allotment status on JM Pro app: 

• Log in to the JM Pro app. 
• Go to the IPO Section and then to IPO Orders. 
• Select the individual IPO that you had applied for and check the allotment status. 

JM Financial Services will notify you of your IPO allotment status via push notification and email

Frequently Asked Questions (FAQs)

Q1: Can I apply for both IPOs?

A: Yes, the dates overlap perfectly (Dec 8–10). If you have sufficient funds, you can apply for both to maximize your chances of allotment.

Q2: What is the minimum investment for Corona Remedies?

A: For retail investors, the minimum lot size is 14 shares, which requires an investment of ₹14,868 at the upper price band of ₹1,062.

Q3: Is Wakefit technically a loss-making company?

A: Not anymore. While they posted losses in FY23, FY24, and FY25, they reported a Net Profit of ₹35.57 Crore for the first six months of FY26 (April-Sept 2025).

Q4: What is the GMP for Corona Remedies today?

A: As of December 7, 2025, the GMP for Corona Remedies is approximately ₹330, implying a listing premium of roughly 31%.

Q5: When will the shares list on the stock market?

A: Both Wakefit Innovations and Corona Remedies are tentatively scheduled to list on BSE and NSE on Monday, December 15, 2025.